Susquehanna International Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Susquehanna International Group’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.82M	Buy	54,600 +30,300	+125%	+$1.54M	﹤0.01%	5391
2025 Q4	$1.21M	Buy	+24,300	New	+$1.18M	﹤0.01%	6756
2024 Q4	–	Sell	-8,700	Closed	-$271K	–	13187
2024 Q3	$271K	Buy	8,700 +800	+10%	+$25K	﹤0.01%	9809
2024 Q2	$211K	Sell	7,900 -16,800	-68%	-$487K	﹤0.01%	10244
2024 Q1	$843K	Buy	24,700 +16,700	+209%	+$497K	﹤0.01%	7294
2023 Q4	$232K	Buy	+8,000	New	+$212K	﹤0.01%	10371
2023 Q3	–	Sell	-9,000	Closed	-$271K	–	12941
2023 Q2	$271K	Buy	+9,000	New	+$315K	﹤0.01%	9651
2022 Q4	–	Sell	-9,900	Closed	-$335K	–	13627
2022 Q3	$335K	Buy	9,900 +1,000	+11%	+$32.5K	﹤0.01%	9503
2022 Q2	$257K	Sell	8,900 -14,100	-61%	-$404K	﹤0.01%	9976
2022 Q1	$743K	Sell	23,000 -1,700	-7%	-$52.1K	﹤0.01%	7918
2021 Q4	$720K	Buy	24,700 +8,200	+50%	+$249K	﹤0.01%	8171
2021 Q3	$440K	Buy	16,500 +4,300	+35%	+$115K	﹤0.01%	9716
2021 Q2	$376K	Buy	+12,200	New	+$374K	﹤0.01%	10285
2021 Q1	–	Sell	-16,300	Closed	-$410K	–	12828
2020 Q4	$410K	Sell	16,300 -2,800	-15%	-$60.3K	﹤0.01%	8688
2020 Q3	$398K	Buy	+19,100	New	+$433K	﹤0.01%	8142
2020 Q1	–	Sell	-46,600	Closed	-$1.1M	–	10865
2019 Q4	$1.1M	Sell	46,600 -41,100	-47%	-$998K	﹤0.01%	5335
2019 Q3	$2.41M	Sell	87,700 -96,800	-52%	-$2.87M	﹤0.01%	3849
2019 Q2	$6.11M	Sell	184,500 -25,600	-12%	-$877K	﹤0.01%	2450
2019 Q1	$7.36M	Buy	210,100 +75,700	+56%	+$2.82M	﹤0.01%	2044
2018 Q4	$4.46M	Buy	134,400 +12,800	+11%	+$550K	﹤0.01%	2413
2018 Q3	$6.12M	Buy	121,600 +12,300	+11%	+$607K	﹤0.01%	2437
2018 Q2	$6.54M	Sell	109,300 -10,500	-9%	-$544K	﹤0.01%	2413
2018 Q1	$5.49M	Buy	119,800 +20,000	+20%	+$835K	﹤0.01%	2430
2017 Q4	$3.98M	Sell	99,800 -56,900	-36%	-$2.25M	﹤0.01%	2830
2017 Q3	$6.27M	Buy	156,700 +85,700	+121%	+$3.71M	﹤0.01%	2239
2017 Q2	$3.06M	Buy	71,000 +23,700	+50%	+$844K	﹤0.01%	3112
2017 Q1	$1.48M	Buy	47,300 +11,800	+33%	+$316K	﹤0.01%	4307
2016 Q4	$896K	Sell	35,500 -5,000	-12%	-$112K	﹤0.01%	5765
2016 Q3	$1M	Sell	40,500 -10,900	-21%	-$247K	﹤0.01%	4799
2016 Q2	$1.05M	Buy	51,400 +14,600	+40%	+$259K	﹤0.01%	4796
2016 Q1	$561K	Sell	36,800 -53,700	-59%	-$701K	﹤0.01%	6204
2015 Q4	$1.22M	Buy	90,500 +3,200	+4%	+$49.5K	﹤0.01%	5031
2015 Q3	$1.23M	Sell	87,300 -19,300	-18%	-$359K	﹤0.01%	5271
2015 Q2	$1.81M	Buy	106,600 +12,200	+13%	+$174K	﹤0.01%	4941
2015 Q1	$1.14M	Buy	94,400 +7,900	+9%	+$74.6K	﹤0.01%	5478
2014 Q4	$718K	Buy	86,500 +3,700	+4%	+$31.1K	﹤0.01%	6511
2014 Q3	$720K	Buy	82,800 +33,300	+67%	+$301K	﹤0.01%	6545
2014 Q2	$542K	Sell	49,500 -75,100	-60%	-$669K	﹤0.01%	7308
2014 Q1	$1.11M	Sell	124,600 -30,500	-20%	-$281K	﹤0.01%	5333
2013 Q4	$1.17M	Buy	155,100 +19,400	+14%	+$136K	﹤0.01%	5229
2013 Q3	$995K	Buy	135,700 +78,800	+138%	+$529K	﹤0.01%	5282
2013 Q2	$366K	Buy	+56,900	New	+$335K	﹤0.01%	6501

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group's SUPN Position: Q1 2026 in Review

Susquehanna International Group reduced its Supernus Pharmaceuticals (SUPN) stake by 2.9% in Q1 2026, selling an estimated $62.8K and leaving 40,750 shares worth $2.11M. The position accounts for ﹤0.01% of the portfolio, ranked #6062.

Susquehanna International Group first reported a position in SUPN in Q2 2013 and has held it in 47 quarters since. The position peaked at $4.5M in Q4 2016. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

Susquehanna International Group held 40,750 shares of Supernus Pharmaceuticals worth $2.11M as of Q1 2026.
Susquehanna International Group sold 1,234 Supernus Pharmaceuticals shares in Q1 2026, an estimated $62.8K.
Supernus Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6062 holding.
Susquehanna International Group first reported a position in Supernus Pharmaceuticals in Q2 2013 and has held it in 47 quarters since.
Susquehanna International Group's Supernus Pharmaceuticals position peaked at $4.5M in Q4 2016.
327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.